The guidelines are summarized in Table 1, and the processes through which each were constructed are explained and compared below. The most recent NCCN guideline was written by their antiemetic ...

“We are very pleased with NCCN’s update of the NCCN Guidelines to include naxitamab-gggk (DANYELZA). We believe this decision reinforces the importance of naxitimab-gggk (DANYELZA) as a ...